URGN vs. ADVM

Last updated Apr 2, 2026

Compare and contrast key facts about UroGen Pharma Ltd. (URGN) and Adverum Biotechnologies, Inc. (ADVM).

Performance

URGN vs. ADVM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in UroGen Pharma Ltd. (URGN) and Adverum Biotechnologies, Inc. (ADVM). The values are adjusted to include any dividend payments, if applicable.

URGN vs. ADVM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
URGN UroGen Pharma Ltd.	-19.13%	119.91%	-29.00%	69.11%	-6.73%	-47.23%	-46.00%	-22.50%	15.72%	166.17%
ADVM Adverum Biotechnologies, Inc.	0.00%	-6.64%	-37.96%	29.91%	-67.07%	-83.76%	-5.90%	265.71%	-10.00%	22.81%

Fundamentals

Market Cap URGN : $932.42M ADVM : $102.40M
EPS URGN : -$3.18 ADVM : -$9.19
Total Revenue (TTM) URGN : $109.79M ADVM : $0.00
Gross Profit (TTM) URGN : $97.34M ADVM : -$465.00K
EBITDA (TTM) URGN : -$127.69M ADVM : -$205.45M

Returns By Period

URGN

• 1D: 5.34%
• 1M: -0.42%
• YTD: -19.13%
• 6M: 6.31%
• 1Y: 78.17%
• 3Y*: 27.03%
• 5Y*: -0.71%
• 10Y*: —

ADVM

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: -12.97%
• 1Y: 13.84%
• 3Y*: -15.30%
• 5Y*: -46.64%
• 10Y*: -21.95%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

URGN vs. ADVM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

URGN

URGN Risk / Return Rank: 69
URGN Sharpe Ratio Rank: 65
URGN Sortino Ratio Rank: 73
URGN Omega Ratio Rank: 76
URGN Calmar Ratio Rank: 64
URGN Martin Ratio Rank: 66

ADVM

ADVM Risk / Return Rank: 46
ADVM Sharpe Ratio Rank: 47
ADVM Sortino Ratio Rank: 53
ADVM Omega Ratio Rank: 52
ADVM Calmar Ratio Rank: 39
ADVM Martin Ratio Rank: 40

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

URGN vs. ADVM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and Adverum Biotechnologies, Inc. (ADVM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	URGN	ADVM	Difference
Sharpe ratio Return per unit of total volatility	0.69	0.20	+0.49
Sortino ratio Return per unit of downside risk	1.78	0.96	+0.81
Omega ratio Gain probability vs. loss probability	1.27	1.12	+0.14
Calmar ratio Return relative to maximum drawdown	1.08	-0.02	+1.09
Martin ratio Return relative to average drawdown	3.00	-0.03	+3.03
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

URGN vs. ADVM - Sharpe Ratio Comparison

The current URGN Sharpe Ratio is 0.69, which is higher than the ADVM Sharpe Ratio of 0.20. The chart below compares the historical Sharpe Ratios of URGN and ADVM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	URGN	ADVM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.69	0.20	+0.49
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.01	-0.58	+0.57
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.27	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.04	-0.32	+0.36

Correlation

The correlation between URGN and ADVM is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

URGN vs. ADVM - Dividend Comparison

Neither URGN nor ADVM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

URGN vs. ADVM - Drawdown Comparison

The maximum URGN drawdown since its inception was -93.98%, smaller than the maximum ADVM drawdown of -99.20%. Use the drawdown chart below to compare losses from any high point for URGN and ADVM.

Drawdown Indicators

	URGN	ADVM	Difference
Max Drawdown Largest peak-to-trough decline	-93.98%	-99.20%	+5.22%
Max Drawdown (1Y) Largest decline over 1 year	-66.24%	-51.88%	-14.36%
Max Drawdown (5Y) Largest decline over 5 years	-82.64%	-98.06%	+15.42%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.20%	—
Current Drawdown Current decline from peak	-71.01%	-98.30%	+27.29%
Average Drawdown Average peak-to-trough decline	-61.55%	-69.23%	+7.68%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.79%	37.59%	-13.80%

Volatility

URGN vs. ADVM - Volatility Comparison

UroGen Pharma Ltd. (URGN) has a higher volatility of 15.35% compared to Adverum Biotechnologies, Inc. (ADVM) at 0.00%. This indicates that URGN's price experiences larger fluctuations and is considered to be riskier than ADVM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	URGN	ADVM	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.35%	0.00%	+15.35%
Volatility (6M) Calculated over the trailing 6-month period	49.37%	49.41%	-0.04%
Volatility (1Y) Calculated over the trailing 1-year period	113.74%	84.03%	+29.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.48%	82.34%	+9.14%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.73%	81.87%	-2.14%

Financials